Fresenius Gets PTAB To Deal Another Blow On Cubicin Patents

By Matthew Bultman (May 12, 2016, 7:12 PM EDT) -- Cubist Pharmaceuticals was dealt another setback in its ongoing fight to preserve patents on its blockbuster antibiotic Cubicin as the Patent Trial and Appeal Board ruled Thursday that various claims in two of its patents were invalid, in favor of Fresenius....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!